MedPath

Passage Bio Inc.

Passage Bio Inc. logo
🇺🇸United States
Ownership
Public
Established
2018-01-01
Employees
101
Market Cap
$45.8M
Website
http://www.passagebio.com

Clinical Trials

6

Active:3
Completed:0

Trial Phases

2 Phases

Phase 1:5
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
5 (83.3%)
Phase 2
1 (16.7%)

Study of Safety, Tolerability and Efficacy of PBKR03 in Pediatric Subjects With Early Infantile Krabbe Disease

Phase 1
Suspended
Conditions
Leukodystrophy, Globoid Cell
First Posted Date
2021-02-25
Last Posted Date
2024-01-18
Lead Sponsor
Passage Bio, Inc.
Target Recruit Count
24
Registration Number
NCT04771416
Locations
🇺🇸

Ann & Robert Lurie, Chicago, Illinois, United States

🇺🇸

New York-Presbyterian, New York, New York, United States

🇺🇸

The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 6 locations

A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes

Phase 1
Recruiting
Conditions
Frontotemporal Dementia
FTD
FTD-GRN
Dementia Frontotemporal
C9orf72
Interventions
First Posted Date
2021-02-10
Last Posted Date
2025-01-24
Lead Sponsor
Passage Bio, Inc.
Target Recruit Count
25
Registration Number
NCT04747431
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

🇺🇸

University of Texas at Houston, Houston, Texas, United States

🇧🇷

Hospital das Clinicas da Universidade Federal de Minas Gerais (UFMG), Minas Gerais, Brazil

and more 4 locations

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

Phase 1
Active, not recruiting
Conditions
Beta-Galactosidase-1 (GLB1) Deficiency
GM1 Gangliosidosis, Type I
GM1 Gangliosidosis, Type 2
GM1 Gangliosidosis
Interventions
First Posted Date
2021-01-19
Last Posted Date
2025-05-21
Lead Sponsor
Gemma Biotherapeutics
Target Recruit Count
26
Registration Number
NCT04713475
Locations
🇺🇸

Benioff Children's Hospital, Oakland, California, United States

🇺🇸

University of Minnesota, Minneapolis, Minnesota, United States

🇺🇸

Children's Hospital at St. Peter's University Hospital, New Brunswick, New Jersey, United States

and more 4 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.